Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C5H10O5 |
Molecular Weight | 150.1299 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC[C@@H](O)[C@@H](O)[C@@H](O)C=O
InChI
InChIKey=PYMYPHUHKUWMLA-LMVFSUKVSA-N
InChI=1S/C5H10O5/c6-1-3(8)5(10)4(9)2-7/h1,3-5,7-10H,2H2/t3-,4+,5-/m0/s1
Molecular Formula | C5H10O5 |
Molecular Weight | 150.1299 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
D-ribose, a naturally occurring pentose carbohydrate, and a key component in the adenosine triphosphate (ATP) molecule. D-ribose was studied for congestive heart failure. In addition was discovered, that D-ribose significantly reduced clinical symptoms in patients suffering from fibromyalgia and chronic fatigue syndrome. Recently was published an article where were described, that d-Ribose reacted with the N-terminal valinyl residues of hemoglobin (Hb), thus producing glycated hemoglobin (HbA1c). It is known, that HbA1c is the most important marker of hyperglycemia in diabetes mellitus, which prompts future studies to explore whether D-ribose could also lead to diabetic complications.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2095168 Sources: https://www.ncbi.nlm.nih.gov/pubmed/29033370 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25701016
oral D-ribose (5 g/dose) for 6 weeks
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/29033370
D-ribose (0.5 mM) was added to foetal calf serum or human urine at 37 °C, and aliquots were collected and used for measurement of D-ribose at different time intervals (0, 2, 4, 6, 8, 24, 36, 48, and 72 h). Haemoglobin (10 mg/ml) was incubated with different concentrations of D-ribose (0, 1, 20, 50, 100, and 200 mM) for 5 days, and aliquots were collected and used for the detection of HbA1c each day. Haemoglobin (10 mg/ml) was incubated with 0.2 mM D-ribose or 7 mM D-glucose (0, 6, 12, 24, 36, 48, 72, and 96 h), and aliquots were collected and used for detection of HbA1c at each interval. HbA1c was determined with an ELISA kit for human HbA1c. D-ribose reacted with the N-terminal valinyl residues of Hb, thus producing significantly higher HbA1c levels (P < 0.001) than D-glucose after three days of incubation with 0.1 M D-ribose or 0.1 M D-glucose. This result demonstrated that both D-ribose and D-glucose glycate Hb and produce HbA1c.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:20:12 GMT 2023
by
admin
on
Fri Dec 15 15:20:12 GMT 2023
|
Record UNII |
681HV46001
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LOINC |
2926-4
Created by
admin on Fri Dec 15 15:20:12 GMT 2023 , Edited by admin on Fri Dec 15 15:20:12 GMT 2023
|
||
|
DSLD |
1711 (Number of products:221)
Created by
admin on Fri Dec 15 15:20:12 GMT 2023 , Edited by admin on Fri Dec 15 15:20:12 GMT 2023
|
||
|
NCI_THESAURUS |
C68484
Created by
admin on Fri Dec 15 15:20:12 GMT 2023 , Edited by admin on Fri Dec 15 15:20:12 GMT 2023
|
||
|
DSLD |
712 (Number of products:2)
Created by
admin on Fri Dec 15 15:20:12 GMT 2023 , Edited by admin on Fri Dec 15 15:20:12 GMT 2023
|
||
|
LOINC |
32268-5
Created by
admin on Fri Dec 15 15:20:12 GMT 2023 , Edited by admin on Fri Dec 15 15:20:12 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID6043917
Created by
admin on Fri Dec 15 15:20:12 GMT 2023 , Edited by admin on Fri Dec 15 15:20:12 GMT 2023
|
PRIMARY | |||
|
SUB128226
Created by
admin on Fri Dec 15 15:20:12 GMT 2023 , Edited by admin on Fri Dec 15 15:20:12 GMT 2023
|
PRIMARY | |||
|
RIBOSE
Created by
admin on Fri Dec 15 15:20:12 GMT 2023 , Edited by admin on Fri Dec 15 15:20:12 GMT 2023
|
PRIMARY | |||
|
200-059-4
Created by
admin on Fri Dec 15 15:20:12 GMT 2023 , Edited by admin on Fri Dec 15 15:20:12 GMT 2023
|
PRIMARY | |||
|
681HV46001
Created by
admin on Fri Dec 15 15:20:12 GMT 2023 , Edited by admin on Fri Dec 15 15:20:12 GMT 2023
|
PRIMARY | |||
|
27476
Created by
admin on Fri Dec 15 15:20:12 GMT 2023 , Edited by admin on Fri Dec 15 15:20:12 GMT 2023
|
PRIMARY | |||
|
SUB32509
Created by
admin on Fri Dec 15 15:20:12 GMT 2023 , Edited by admin on Fri Dec 15 15:20:12 GMT 2023
|
PRIMARY | |||
|
100
Created by
admin on Fri Dec 15 15:20:12 GMT 2023 , Edited by admin on Fri Dec 15 15:20:12 GMT 2023
|
PRIMARY | |||
|
243
Created by
admin on Fri Dec 15 15:20:12 GMT 2023 , Edited by admin on Fri Dec 15 15:20:12 GMT 2023
|
PRIMARY | |||
|
10257-32-6
Created by
admin on Fri Dec 15 15:20:12 GMT 2023 , Edited by admin on Fri Dec 15 15:20:12 GMT 2023
|
ALTERNATIVE | |||
|
47013
Created by
admin on Fri Dec 15 15:20:12 GMT 2023 , Edited by admin on Fri Dec 15 15:20:12 GMT 2023
|
PRIMARY | |||
|
47014
Created by
admin on Fri Dec 15 15:20:12 GMT 2023 , Edited by admin on Fri Dec 15 15:20:12 GMT 2023
|
PRIMARY | |||
|
613-83-2
Created by
admin on Fri Dec 15 15:20:12 GMT 2023 , Edited by admin on Fri Dec 15 15:20:12 GMT 2023
|
ALTERNATIVE | |||
|
1603108
Created by
admin on Fri Dec 15 15:20:12 GMT 2023 , Edited by admin on Fri Dec 15 15:20:12 GMT 2023
|
PRIMARY | |||
|
5311110
Created by
admin on Fri Dec 15 15:20:12 GMT 2023 , Edited by admin on Fri Dec 15 15:20:12 GMT 2023
|
PRIMARY | |||
|
33942
Created by
admin on Fri Dec 15 15:20:12 GMT 2023 , Edited by admin on Fri Dec 15 15:20:12 GMT 2023
|
PRIMARY | |||
|
1314858
Created by
admin on Fri Dec 15 15:20:12 GMT 2023 , Edited by admin on Fri Dec 15 15:20:12 GMT 2023
|
PRIMARY | RxNorm | ||
|
50-69-1
Created by
admin on Fri Dec 15 15:20:12 GMT 2023 , Edited by admin on Fri Dec 15 15:20:12 GMT 2023
|
PRIMARY | |||
|
681HV46001
Created by
admin on Fri Dec 15 15:20:12 GMT 2023 , Edited by admin on Fri Dec 15 15:20:12 GMT 2023
|
PRIMARY | |||
|
DB15073
Created by
admin on Fri Dec 15 15:20:12 GMT 2023 , Edited by admin on Fri Dec 15 15:20:12 GMT 2023
|
PRIMARY | |||
|
100000124325
Created by
admin on Fri Dec 15 15:20:12 GMT 2023 , Edited by admin on Fri Dec 15 15:20:12 GMT 2023
|
PRIMARY | |||
|
16988
Created by
admin on Fri Dec 15 15:20:12 GMT 2023 , Edited by admin on Fri Dec 15 15:20:12 GMT 2023
|
PRIMARY | |||
|
m9598
Created by
admin on Fri Dec 15 15:20:12 GMT 2023 , Edited by admin on Fri Dec 15 15:20:12 GMT 2023
|
PRIMARY | Merck Index | ||
|
C68487
Created by
admin on Fri Dec 15 15:20:12 GMT 2023 , Edited by admin on Fri Dec 15 15:20:12 GMT 2023
|
PRIMARY | |||
|
45506
Created by
admin on Fri Dec 15 15:20:12 GMT 2023 , Edited by admin on Fri Dec 15 15:20:12 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |